Literature DB >> 19332202

Late coronary intervention for totally occluded left anterior descending coronary arteries in stable patients after myocardial infarction: Results from the Occluded Artery Trial (OAT).

Lukasz A Malek1, Harmony R Reynolds, Sandra A Forman, Carlos Vozzi, G B John Mancini, John K French, Mieczyslaw Dziarmaga, Jean P Renkin, Janusz Kochman, Gervasio A Lamas, Judith S Hochman.   

Abstract

BACKGROUND: We analyzed a prespecified hypothesis of the Occluded Artery Trial (OAT) that late percutaneous coronary intervention (PCI) of the infarct-related artery (IRA) would be most beneficial for patients with anterior myocardial infarction (MI).
METHODS: Two thousand two hundred one stable, high-risk patients with total occlusion of the IRA (793 left anterior descending [LAD]) on days 3 to 28 (minimum of 24 hours) after MI were randomized to PCI and stenting with optimal medical therapy (1,101 patients) or to optimal medical therapy alone (1,100 patients). The primary end point was a composite of death, recurrent MI, or hospitalization for class IV heart failure.
RESULTS: The 5-year cumulative primary end point rate was more frequent in the LAD group (19.5%) than in the non-LAD group (16.4%) (HR 1.34, 99% CI 1.00-1.81, P = .01). Within the LAD group, the HR for the primary end point in the PCI group (22.7%) compared with the medical therapy group (16.4%) was 1.35 (99% CI 0.86-2.13, P = .09), whereas in the non-LAD group the HR for the primary end point in PCI (16.9%) compared with medical therapy (15.8%) was 1.03 (99% CI 0.70-1.52, P = .83) (interaction P = .24). The results were similar when the effect of PCI was assessed in patients with proximal LAD occlusion.
CONCLUSIONS: In stable patients, persistent total occlusion of the LAD post MI is associated with a worse prognosis compared with occlusion of the other IRAs. A strategy of PCI of occluded LAD IRA >24 hours post MI in stable patients is not beneficial and may increase risk of adverse events in comparison to optimal medical treatment alone.

Entities:  

Mesh:

Year:  2009        PMID: 19332202      PMCID: PMC2696388          DOI: 10.1016/j.ahj.2008.12.008

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  17 in total

1.  Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE).

Authors:  Kim A Eagle; Shaun G Goodman; Alvaro Avezum; Andrzej Budaj; Cynthia M Sullivan; José López-Sendón
Journal:  Lancet       Date:  2002-02-02       Impact factor: 79.321

2.  Late intervention after anterior myocardial infarction: effects on left ventricular size, function, quality of life, and exercise tolerance: results of the Open Artery Trial (TOAT Study).

Authors:  Zaheer R Yousef; Simon R Redwood; Clifford A Bucknall; Alfred N Sulke; Michael S Marber
Journal:  J Am Coll Cardiol       Date:  2002-09-04       Impact factor: 24.094

3.  Out-of-hospital ventricular fibrillation in patients with acute myocardial infarction: coronary angiographic determinants.

Authors:  P J Gheeraert; J P Henriques; M L De Buyzere; J Voet; P Calle; Y Taeymans; F Zijlstra
Journal:  J Am Coll Cardiol       Date:  2000-01       Impact factor: 24.094

4.  Determinants and prognostic significance of collaterals in patients undergoing coronary revascularization.

Authors:  Hendrik M Nathoe; Jeroen Koerselman; Erik Buskens; Diederik van Dijk; Pieter R Stella; Thijs H W Plokker; Pieter A F M Doevendans; Diederick E Grobbee; Peter P T de Jaegere
Journal:  Am J Cardiol       Date:  2006-05-03       Impact factor: 2.778

Review 5.  Reperfusion strategies in acute ST-segment elevation myocardial infarction: a comprehensive review of contemporary management options.

Authors:  William E Boden; Kim Eagle; Christopher B Granger
Journal:  J Am Coll Cardiol       Date:  2007-08-21       Impact factor: 24.094

6.  Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction.

Authors:  David E Kandzari; James E Tcheng; Bernard J Gersh; David A Cox; Thomas Stuckey; Mark Turco; Roxana Mehran; Eulogio Garcia; Peter Zimetbaum; Michael G McGlaughlin; Alexandra J Lansky; Costantino O Costantini; Cindy L Grines; Gregg W Stone
Journal:  Am Heart J       Date:  2006-06       Impact factor: 4.749

7.  Coronary intervention for persistent occlusion after myocardial infarction.

Authors:  Judith S Hochman; Gervasio A Lamas; Christopher E Buller; Vladimir Dzavik; Harmony R Reynolds; Staci J Abramsky; Sandra Forman; Witold Ruzyllo; Aldo P Maggioni; Harvey White; Zygmunt Sadowski; Antonio C Carvalho; Jamie M Rankin; Jean P Renkin; P Gabriel Steg; Alice M Mascette; George Sopko; Matthias E Pfisterer; Jonathan Leor; Viliam Fridrich; Daniel B Mark; Genell L Knatterud
Journal:  N Engl J Med       Date:  2006-11-14       Impact factor: 91.245

8.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

9.  Role of collateral circulation in the acute phase of ST-segment-elevation myocardial infarction treated with primary coronary intervention.

Authors:  P Elsman; A W J van 't Hof; M J de Boer; J C A Hoorntje; H Suryapranata; J H E Dambrink; F Zijlstra
Journal:  Eur Heart J       Date:  2004-05       Impact factor: 29.983

10.  Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients.

Authors:  Eric Boersma
Journal:  Eur Heart J       Date:  2006-03-02       Impact factor: 29.983

View more
  1 in total

Review 1.  Secondary prevention of ischaemic cardiac events.

Authors:  Jane S Skinner; Angela Cooper
Journal:  BMJ Clin Evid       Date:  2011-08-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.